Lite Strategy, Inc.
Lite Strategy, Inc. (NASDAQ: LITS) operates as a pharmaceutical company focused on developing novel and differentiated cancer therapies. The company changed its name from MEI Pharma, Inc. on September 10, 2025, reflecting a strategic pivot in its business model and capital allocation strategy. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Lite Strategy, Inc. does
In the company’s own words
Lite Strategy, Inc. (NASDAQ: LITS) operates as a pharmaceutical company focused on developing novel and differentiated cancer therapies. The company changed its name from MEI Pharma, Inc. on September 10, 2025, reflecting a strategic pivot in its business model and capital allocation strategy.
The company's drug candidate pipeline includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and zandelisib, an oral, once-daily, selective PI3Kδ inhibitor. Voruciclib completed Phase 1 trials evaluating its use in combination with venetoclax for treating acute myeloid leukemia and was previously studied in solid tumors including melanoma. Zandelisib was jointly developed with Kyowa Kirin Co., Ltd under a global license agreement that was terminated in July 2023, with the company regaining full global rights to the asset. Clinical development efforts for both candidates were discontinued as of July 2024, though the company continues to assess pre-clinical development programs for potential non-oncology disease indications.
In July 2025, Lite Strategy closed a $100 million private investment in public equity (PIPE) offering, issuing approximately 23.2 million shares of common stock and pre-funded warrants. The company deployed the net proceeds from this offering to implement a Litecoin Treasury Strategy, acquiring Litecoin tokens as a primary reserve asset and reflecting a strategic shift toward digital asset infrastructure and financial technology innovation. The company also initiated an expanding strategy that could include Litecoin mining activities.
The company's intellectual property portfolio includes exclusive worldwide rights to voruciclib, with 21 allowed or issued U.S. patents projected to expire between 2026 and 2039, and approximately 90 allowed or issued foreign patents. For zandelisib, the company holds nine issued U.S. patents with composition of matter claims projected to expire between 2030 and 2032, and approximately 48 foreign patents granted.
Lite Strategy's approach to oncology drug development emphasizes evaluating drug candidates in combinations with standard-of-care therapies to overcome resistance mechanisms and address clear medical needs. The company operates in a highly competitive pharmaceutical marketplace where numerous competitors possess greater capital resources and development capabilities.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- SAN DIEGO, CA
- Fiscal year end
- June
- CIK
- 1262104
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Lite Strategy, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Lite Strategy, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Lite Strategy, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Lite Strategy, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Lite Strategy, Inc.'s last four quarterly filings that the numbers alone won't show?”